Technology
Health
Pharmaceutical

Biohaven Pharmaceutical

$50.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.44 (-4.58%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BHVN and other stocks, options, ETFs, and crypto commission-free!

About

Biohaven Pharmaceutical Holding Company Ltd., also called Biohaven Pharmaceutical, is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. Read More The company was founded in September 2013 and is headquartered in New Haven, CT.

Employees
63
Headquarters
New Haven, Connecticut
Founded
2013
Market Cap
2.36B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
470.83K
High Today
$53.66
Low Today
$50.60
Open Price
$52.86
Volume
121.23K
52 Week High
$53.66
52 Week Low
$16.50

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Research And Development
2017 IPO
US

News

PR NewswireMar 13

Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant

NEW HAVEN, Conn., March 13, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders, today announced that the Company concluded its pre-New Drug Application ("NDA") meetings with the U.S. Food and Drug Administration ("FDA") for rimegepant Zydis® ODT (orally dissolving tablet) and tablet formulations fo...

65
BenzingaFeb 28

Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial And Recent Business Results

NEW HAVEN, Conn., Feb. 28, 2019 /PRNewswire/ --Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting central nervous system diseases, including rare neurological disorders, today reported financial results for the fourth quarter and year ended December 31, 2018, and provided a review of recent accomplishments and anticipated upcoming milestones. "In 2018, we achieved significant progress a...

118

Earnings

-$2.32
-$1.75
-$1.18
-$0.61
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 14, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.